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dicates that PD-L1+ TIM and PD-L1 margin expression were indepen-
dently predictive in absence of HPV, the interaction between CTL/Treg
ratio and PD-L1+ TIM was predictive irrespectively of HPV-status.
CONCLUSIONS: A PD-L1 expression pattern predominantly at
the tumor-stroma margin predicts good prognosis, while the negative
predictive value of PD-L1+ TIM appear to be compensated by a high
CTL/Treg ratio. All independent prognostic factors are PD-L1 related
parameters. These results strengthen the rationale for anti-PD-1/PD-L1
immunotherapy in penile carcinoma.
Source of Funding: none.MP44-19
HIGH-THROUGHPUT CHEMICAL SCREENING FOR
SENSITIZATION OF BLADDER CANCER TO GEMCITABINE
AND CISPLATIN CHEMOTHERAPYYuki Kita*, Takashi Kobayashi, Atsuro Sawada, Ryouichi Saito,
Toshinari Yamasaki, Takahiro Inoue, Osamu Ogawa, Kyoto, Japan
INTRODUCTION AND OBJECTIVES: Gemcitabine and
cisplatin chemotherapy (GC) is the current standard regimen for locally
advanced and metastatic bladder cancer (BC). Despite a relatively high
initial response rate, some cases do not regress (intrinsic resistance)
and the remaining cases often show regrowth after initial shrinkage
(acquired resistance). To identify novel therapeutic agents for over-
coming these resistances, we applied a high-throughput screening of
chemicals administered in combination with GC.
METHODS: As a high-throughput screening, 2100 compounds
were administered alone or in combination with GC to human BC cell
lines (J82, UMUC-3). Cell viability was determined after 3-day incuba-
tion and chemicals that enhanced inhibitory effect of GC were screened.
The in vivo effect of disulﬁram (DSF) was studied in UMUC-3 cell xe-
nografts, and western blot, immunoﬂuorescence, induced coupled
plasma spectrometry and measurement of reactive oxygen species
(ROS) were done in vitro for mechanistic exploration.
RESULTS: The initial screening identiﬁed 26 compounds and
further validation narrowed them into the most synergistic agent disul-
ﬁram, an FDA-approved drug for alcoholism. Combination index assay
showed synergistic effects of DSF with cisplatin but not with gemcita-
bine in J82, UMUC-3, T24, HT1197 and HT1376 cells. Co-administra-
tion of DSF signiﬁcantly increased DNA-platinum adducts by regulating
cisplatin efﬂux transporter ATP7A and enhanced apoptosis by GC
treatment in UMUC-3 cells, with signiﬁcant increase of ROS production.
Use of DSF in combination with GC (GCD) signiﬁcantly inhibited tumor
growth of UMUC-3 subcutaneous xenograft on athymic mice (by 39%
compared with GC alone, p ¼ 0.02). GCD regimen was as tolerable as
GC and no signiﬁcant differences were observed in body weight of
treated mice between the two regimens.
CONCLUSIONS: Repositioning of DSF to a chemotherapy
sensitizer is a promising treatment strategy, which can be translated
rapidly in the future.Source of Funding: noneMP44-20
EGFR CELL EXPRESSION IN BLADDER WASHINGS
AS A RISK MARKER TOOL IN NON MUSCLE-INVASIVE
BLADDER CANCER. PRELIMINARY EXPERIENCEFabrizio Di Maida*, Vincenzo Serretta, Cristina Scalici Gesolfo,
Marco Vella, Antonella Cangemi, Antonio Russo, Alchiede Simonato,
GSTU Foundation, Palermo, Italy
INTRODUCTION AND OBJECTIVES: Up to day, EGFR
expression has been determined mainly in tissue specimens of muscle-
invasive bladder cancer and its overexpression has been associated
with worse prognosis and shorter survival. Urothelial EGFR status after
NMIBC transurethral resection (TUR) could indicate the risk of recur-
rence and progression. We investigated the feasibility of EGFR mea-
surement in bladder washings of patients undergoing intravesical
adjuvant therapy for NMIBC and its usefulness in identifying risk
subgroups.
METHODS: Our prospective study included patients after TUR
of NMIBC and healthy controls. A cellular pellet was obtained from
bladder washing, and RNA extraction performed by miRNeasy Mini Kit
(Qiagen). Good quality of RNA was checked. The cDNA obtained
from RNA was used to perform a gene expression analysis by a Real
Time PCR, according to the method of the comparative quantiﬁcation
(DDCt) with an endogenous control (Cyclophilin). Every reaction was
set in triplicate as a guarantee of quality. Patients were grouped for EAU
risk class and maintained in follow-up. The EGFR expressions were
statistically analyzed according to EAU risk groups and to patients0
outcome. EGFR gene expression values were expressed in FOLDs of
change compared to healthy controls (EGFR¼1).
RESULTS: Fifty-eight patients and 21 healthy age-matched
controls were entered. An adequate cellular pellet was obtained in 50
patients (86.2%) showing a median EGFR expression of 2.0 folds (IQR
0.6-4.3, p¼0.0004). After TUR and adjuvant intravesical therapy, 22
(55%) out of 40 high-risk patients, showed EGFR decrease to 1.3 folds
(IQR 0.9-1.5), while 18 (45%) showed elevated EGFR, median 4.7 (IQR
4.1-11.6). At 25 months median follow-up (IQR 19.0-34.8), 20 (40%)
patients recurred and 6 (12%) progressed. Among patients with or
without EGFR gene increase, 9 (22.5%) and 5 (12.5%) recurred and 5
(12.5%) and 1 (2.5%) progressed, respectively.
CONCLUSIONS: In our experience EGFR expression mea-
surement was feasible in more than 85% of patients and resulted
related to EAU risk classes for recurrence and progression, showing
different behavior during intravesical therapy. It was possible to identify
a subgroup of high risk patients overexpressing EGFR in spite of
intravesical adjuvant therapy. EGFR evaluation in bladder washing
could represent a repeatable and useful tool to identify a subgroup of
patients at risk for progression unresponsive to intravesical adjuvant
therapy and candidate to early radical cystectomy.
Source of Funding: none
